Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: One institution study

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2212-2219

  Todorovic, Milena ^a,b   Balint, Bela ^b,c   Andjelic, Bosko ^a   Stanisavljevic, Dejana ^b,d   Kurtovic, Nada Kraguljac ^a   Radisavljevic, Ziv ^e   Mihaljevic, Biljana ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF DEFENCE   (Serbia)

^d Institute for Medical Statistics and Informatics   (Serbia)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

IPI; Mantle cell lymphoma; MIPI; MIPIb; SMIPI

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; COLONOSCOPY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84872819708     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0136-1     Document Type: Article

References (35)

1. Harris NL, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-92.
2. Raffeld M, Jaffe ES. Bcl-1, t (11; 14), and mantle cell-derived lymphomas. Blood. 1991;78:259-63.
3. Matutes E, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leukemia Lymphoma. 2004;45:2007-15.
4. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-27.
5. Weisenburger DD, Armitage JO. Mantle cell lymphoma; an entity comes of age. Blood. 1996;87:4483-94.
6. Shipp M, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
7. Hoster E, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008;111:558-65.
8. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-95.
9. Wood BL, et al. 2006 Bethesda international consensus recommendation on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: oprimal reagents and reporting for the flow cytometric diagnosis of hematopoietic heoplasia. Cytom Part B (Clin Cytom). 2007;72B:14-22.
10. Boyum A, et al. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21:77-89.
11. Moreau EJ, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Hematopathology. 1997;108:378-82.
12. Matutes E, Attygalle A, Wotherspoon A, Catovsky D. Diagnostic issues in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Hematol. 2010;23:3-20.
13. Foran JM, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117-21.
14. Ghielmini M, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705-11.
15. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114:1469-76.
16. Howard OM, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20:1288-94.
17. Schulz H, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007; 99:706-14.
18. Geisler CH, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530-3.
19. Determann O, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385-7.
20. Katzenberger T, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.
21. Schrader C, et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer. 2005;93:939-45.
22. Schrader C, et al. Repp 86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol. 2005;75:498-504.
23. Schrader C, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18:1200-6.
24. Tiemann M, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29-38.
25. Schaffel R, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21:133-9.
26. Räty R, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002;69:11-20.
27. Wohlschlaeger CH, Lange HM, Feller AC. Aberrant immunophenotypes of mantle cell lymphomas. Leukemia Lymphoma. 2003;44:269-73.
28. Sriganeshan V, Blom TR, Weissmann DJ. A unique case of mantle cell lymphoma with an aberrant CD5/CD10 immunophenotype and typical morphology. Arch Pathol Lab Med. 2008;132:1346-9.
29. Rummel MJ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23: 3383-9.
30. O'Connor OA, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-84.
31. Fisher RI, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-74.
32. Witzig TE, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23: 5347-456.
33. Wiernik PH, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952-7.
34. Todorovic M, et al. Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma. Med Oncol. 2007;24:413-8.
35. Salar A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274-80.